Look at what is happening to Cassava (SAVA) stock. They announced positive ph 3 data recently for their Alzheimer’s drug, and one of the analyst (likely a short) is questioning data integrity. They lost more than 50% of their market cap (shaved around $2.6B of their market cap) last week. Overall, the stock had been up around 7X since the beginning of this year until a week ago.
I commend LP and the whole advisory team to take this brave step of going with top notch peer reviewed paper in parallel with TLD announcement. My confidence in the top management grows with ever passing day. I am sure it’s tough as hell to remain quiet and disciplined when you have great results, but they are doing what’s best to get DCVAX-L approved by all 4 RAs. A group of investors with short term outlook are anxious, but the management is doing the right thing. In essence, getting a publication & manufacturing facility ready before TLD doesn’t really impact the overall timing of getting the regulatory approvals and ultimately access to therapy for the patients. This strategy will minimize distraction once these PRs come out. Shorts simply hate this as they’ve never dealt with such approach before!
Market Data 
Markets 
AI
